Lv2
130 积分 2025-01-12 加入
Cost-effectiveness analysis of Sacituzumab Tirumotecan as second-line therapy for EGFR-TKI–resistant, EGFR-Mutated advanced NSCLC in China
2个月前
已完结
Cost-utility analysis and drug pricing for tirzepatide for type 2 diabetes in the Chinese market compared with semaglutide
2个月前
已完结
Cost-effectiveness analysis of the use of faricimab in diabetic macular edema in China
2个月前
已关闭
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
3个月前
已完结
Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan
3个月前
已完结
Furmonertinib for EGFR-mutant advanced non-small cell lung cancer: a glittering diamond in the rough of EGFR-TKI
3个月前
已完结
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study
3个月前
已完结
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
3个月前
已完结
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials
3个月前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
3个月前
已完结
皖公网安备34019202002308
